MentalHealthDaily

Customized Transcranial Magnetic Stimulation (TMS) Protocols for Depression & Psychiatric Disorders Based on Personalized Neuroimaging (2023 Evidence)

by GLOOM

Recent advancements in neuroimaging and brain stimulation techniques, particularly Transcranial Magnetic Stimulation (TMS), are revolutionizing the treatment of psychiatric disorders. These technologies, leveraging our understanding of individual brain network architectures, offer the potential for highly personalized treatments. Highlights: Personalization of Treatment: Neuroimaging advancements allow for the personalization of brain stimulation targets, particularly in Transcranial Magnetic …

Genetics of Major Depression vs. Symptom Scales (PHQ-9 & CIDI-SF) (2023 Study)

by GLOOM

Major Depressive Disorder (MDD) presents a significant challenge in mental health, with its complex genetic and symptomatic landscape. Recent research focusing on the UK Biobank data has compared the genetic underpinnings of MDD symptoms assessed by the PHQ-9 and CIDI-SF tools. This comparison has highlighted significant differences in their genetic correlations and implications for understanding …

Esketamine Nasal Spray Effective Last Resort for Treatment-Resistant Depression (TRD)? (2023 Study)

by GLOOM

Treatment-resistant depression (TRD) represents a significant challenge in mental health care, often leaving patients and clinicians in a difficult position after traditional treatments fail. Recent studies, including a prospective, observational study at a leading medical center, have brought new hope in the form of esketamine, a novel antidepressant. Highlights: Esketamine’s Mechanism: Esketamine, the S-enantiomer of …

Analyzing Serum Biomarkers to Predict Antidepressant Efficacy in Depression (2023 Study)

by GLOOM

Depression, a complex and often debilitating mental health condition, affects millions globally. Despite advances in psychiatric medicine, finding the right treatment remains a challenge for many. A recent comprehensive study, however, is shedding light on this issue by examining the role of serum biomarkers in predicting the effectiveness of antidepressant therapy. Highlights: Innovative Approach: This …

Intranasal CRISPR Gene Editing for Anxiety via HTR2A Gene (5-HT2A Receptors) in Mice (2023 Study)

by GLOOM

The innovative use of CRISPR/Cas9 gene-editing technology has taken a leap forward in mental health treatment. A new study has demonstrated the successful noninvasive intranasal delivery of this technology to modify neural circuits in the central nervous system, targeting the HTR2A gene associated with anxiety and depression. This breakthrough offers a glimpse into the future …

Serum Neurofilament Light (sNfL) as Biomarker for Bipolar Disorder? (2024 Study)

by GLOOM

Bipolar Disorder (BD), a complex psychiatric condition, is under constant study to better understand its pathophysiology and improve diagnostic and treatment strategies. Recent research has focused on the role of serum neurofilament light (sNfL), a marker for neuro-axonal injury, in BD. Highlights: Individuals with BD for more than three years exhibit higher sNfL levels compared …

Genetic (Polygenic) Risk for Psychiatric Disorders & Subject-Specific School Grades (2023 Study)

by GLOOM

The intricate connection between mental health and educational attainment is a subject of growing interest and importance. Recent studies have shed light on how genetic predispositions to certain mental disorders can influence academic performance, challenging our understanding of how mental health impacts learning. Highlights: Polygenic Risk Scores Reveal New Insights: Studies utilizing polygenic risk scores …